DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer
The Safe Streaming™ service amasses huge gaming library of classic content and popular hits played by content creators CALGARY, Alberta, Sept. 20, 2021 (GLOBE NEWSWIRE) — A Parent Media Co. Inc. (APMC) is excited to share that its flagship product, Kidoodle.TV®, has bolstered its library of gaming content in a major
HONG KONG, Sept. 20, 2021 (GLOBE NEWSWIRE) — Amber Group recently announced the appointment of former Goldman Sachs Partner Dimitrios Kavvathas as the firm’s new Chief Strategy Officer. In this new role, Dr. Kavvathas will work with Amber Group CEO Michael Wu and the senior leadership team to set the
PHOENIX, Sept. 20, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced that it closed the acquisitions of American Mobile Leasing, Inc., Equipe Container Services, Inc. d/b/a Moveable Container
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021 Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment $355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform MeMed BV is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes MeMed Key is
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION) Jeito I exceeds target and becomes the largest European fund dedicated to the life sciences sector Jeito Capital is dedicated to working with biotech entrepreneurs
